Výsledky vyhledávání

Akademický článek

Clinical implications of circulating tumor DNA in predicting the outcome of diffuse large B cell lymphoma patients receiving first-line therapy

Autor: Miaomiao Li, Lan Mi, Chunyang Wang, Xiaojuan Wang, Jianhua Zhu, Fei Qi, Hui Yu, Yingying Ye, Dedao Wang, Jiaowu Cao, Dingyao Hu, Quanyu Yang, Dandan Zhao, Tonghui Ma, Yuqin Song, Jun Zhu

Publikováno v: BMC Medicine, Vol 20, Iss 1, Pp 1-13 (2022)

Abstract Background Circulating tumor DNA (ctDNA) has been proven to be a promising tumor-specific biomarker in solid tumors, but its clinical utility in risk stratification and early prediction of relapse for diffuse large B cell lymphoma (DLBCL) ha

Externí odkaz: https://doaj.org/article/d6bf640f1dd94c6ba24d54f6e4b69ab7

Zobrazit plný text záznamu

Plný text ve formátu HTML

Ibrutinib combined with low‐dose histone deacetylases inhibitor chidamide synergistically enhances the anti‐tumor effect in B‐cell lymphoma

Autor: Hui Yu, Lan Mi, Weimin Zhang, Yingying Ye, Miaomiao Li, Dingyao Hu, Jiaowu Cao, Dedao Wang, Xiaogan Wang, Ning Ding, Yuqin Song, Jun Zhu

Publikováno v: Hematological Oncology. 40:894-905

Aberrant activity of histone deacetylases (HDACs) is frequently detected in B-cell lymphomas, which indicated the therapeutic implications of HDAC inhibitors for B-cell malignancies. We have discovered that lymphoma cells treated with HDAC inhibitor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ce18ccb61162056612ba910a00a41a73
https://doi.org/10.1002/hon.3056

Zobrazit plný text záznamu

Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma

Autor: Miaomiao Li, Hui Yu, Fei Qi, Yingying Ye, Dingyao Hu, Jiaowu Cao, Dedao Wang, Lan Mi, Zhengyi Wang, Ning Ding, Lingyan Ping, Shaokun Shu, Jun Zhu

Publikováno v: Hematological Oncology. 40:596-608

CD47 expressed on cancer cells enables macrophage immune evasion. Blocking CD47 using anti-CD47 monoclonal antibodies (mAbs) is a promising strategy. The anti-CD47 mAb TJC4 has anti-tumor activity but lacks hematological toxicity. Venetoclax, a B-cel

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c072f5f26f8beebeb8b6b2d120c1fda9
https://doi.org/10.1002/hon.3009

Zobrazit plný text záznamu

Clinical implications of circulating tumor DNA in predicting the outcome of first line treatment in diffuse large B-cell lymphoma (DLBCL) patients

Autor: Miaomiao Li, Lan Mi, Chunyang Wang, Xiaojuan Wang, Jianhua Zhu, Fei Qi, Hui Yu, Yingying Ye, Dedao Wang, Jiaowu Cao, Dingyao Hu, Quanyu Yang, Dandan Zhao, Tonghui Ma, Yuqin Song, Jun Zhu

Background: The clinical implication of circulating tumor DNA (ctDNA) as a prognostic or predictive biomarker in DLBCL patients receiving standard immunochemotherapy is uncertain. Methods: Here, using targeted next-generation sequencing, we assessed

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a783dba4a9df85f32cd923730f89f2b
https://doi.org/10.21203/rs.3.rs-1478293/v1

Zobrazit plný text záznamu

Author response for 'Anti‐CD47 immunotherapy in combination with BCL‐2 inhibitor to enhance anti‐tumor activity in B‐cell lymphoma'

Autor: null Miaomiao Li, null Hui Yu, null Fei Qi, null Yingying Ye, null Dingyao Hu, null Jiaowu Cao, null Dedao Wang, null Lan Mi, null Zhengyi Wang, null Ning Ding, null Lingyan Ping, null Shaokun Shu, null Jun Zhu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::88e802c1ee0dbd4df0353282c471c855
https://doi.org/10.1002/hon.3009/v2/response1

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání